Enhanced Healthcare Partners (EHP), a healthcare-focused private equity firm, has exited its platform investment in SCA Pharmaceuticals (SCA Pharma) through the sale of the business to The Vistria Group and Excellere Capital Management.
An FDA 503(B) outsourcing facility, SCA Pharma delivers sterile admixtures and pre-filled syringes to hospitals and health systems nationwide. SCA alleviates common problems health care facilities face such as wasted product, drug shortages, time-consuming processes, compliance issues, staffing costs, and patient safety concerns. Over the past five years, the Company has deeply invested in facility expansion, infrastructure, automation and quality to support the Company’s growth.
SCA Pharma’s CEO Milton Boyer says: “We are very pleased that as we continue our expansion efforts and improvements in our efficiencies, our new partnership with The Vistria Group and Excellere will allow us to accelerate these efforts. Both partners recognise the unprecedented growth that we have achieved and are committed to fast-tracking our expansion and automation goals.
“We benefitted tremendously from our relationship with Enhanced and are grateful for their insight and support. Our growth under their leadership has been phenomenal.”
“We are proud of what SCA and the team accomplished throughout our partnership and are honored to have played a role assisting the company in its expansion and growth initiatives,” says EHP’s General Partner Matt Thompson. “We wish Milton—and the rest of the management team—the best of luck in this next stage of growth and could not be more confident in SCA’s ability to continue on its trajectory of growth and innovation.”
Terms of the transaction have not disclosed.
William Blair & Company served as exclusive financial advisor and McDermott Will & Emery served as legal counsel to SCA Pharma.
